158 related articles for article (PubMed ID: 8431659)
41. Effects of interleukin-2 on bone resorption and natural immunity in osteopetrotic (ia) rats.
Schneider GB; Relfson M
Lymphokine Cytokine Res; 1994 Dec; 13(6):335-41. PubMed ID: 7703307
[TBL] [Abstract][Full Text] [Related]
42. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells.
Puzanov IJ; Bennett M; Kumar V
J Immunol; 1996 Nov; 157(10):4282-5. PubMed ID: 8906800
[TBL] [Abstract][Full Text] [Related]
43. Effects of a low-pathogen environment on natural killer cells of normal and B lymphocyte-deficient mice.
Christopher FL; Miller SC
Nat Immun Cell Growth Regul; 1991; 10(4):216-25. PubMed ID: 1832742
[TBL] [Abstract][Full Text] [Related]
44. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
Verma UN; Mazumder A
Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
[TBL] [Abstract][Full Text] [Related]
46. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
47. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
48. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
Jackson JD; Yan Y; Ewel C; Talmadge JE
Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
[TBL] [Abstract][Full Text] [Related]
49. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
Condiotti R; Nagler A
Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
[TBL] [Abstract][Full Text] [Related]
50. Natural killer cell development and function precede alpha beta T cell differentiation in mouse fetal thymic ontogeny.
Carlyle JR; Michie AM; Cho SK; Zúñiga-Pflücker JC
J Immunol; 1998 Jan; 160(2):744-53. PubMed ID: 9580246
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
Merluzzi VJ; Trail PA; Last-Barney K
J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
[TBL] [Abstract][Full Text] [Related]
52. Simultaneous development of cells with large granular lymphocyte (LGL) morphology and natural killer (NK) cell lytic activity after bone marrow (BM) transplantation in mice.
Silvennoinen O; Hurme M
Immunology; 1988 Jan; 63(1):105-10. PubMed ID: 3276616
[TBL] [Abstract][Full Text] [Related]
53. Role of CD44 in the development of natural killer cells from precursors in long-term cultures of mouse bone marrow.
Delfino DV; Patrene KD; DeLeo AB; DeLeo R; Herberman RB; Boggs SS
J Immunol; 1994 Jun; 152(11):5171-9. PubMed ID: 7514628
[TBL] [Abstract][Full Text] [Related]
54. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
55. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
56. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
Silva MR; Parreira A; Ascensão JL
Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
[TBL] [Abstract][Full Text] [Related]
57. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
[TBL] [Abstract][Full Text] [Related]
58. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
[TBL] [Abstract][Full Text] [Related]
59. Altered production and renewal of natural killer cells in B-lymphocyte-deficient CBA/N mice.
Miller SC; Christopher FL
Nat Immun Cell Growth Regul; 1989; 8(5):245-54. PubMed ID: 2594018
[TBL] [Abstract][Full Text] [Related]
60. Restrictions in the stem cell function of murine bone marrow grafts after ex vivo expansion of short-term repopulating progenitors.
Varas F; Bernard A; Bueren JA
Exp Hematol; 1998 Feb; 26(2):100-9. PubMed ID: 9472799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
